Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer

BACKGROUND: Significant progress in treatment of metastatic castration resistant prostate cancer (mCRPC) has been made. Biomarkers to tailor therapy are scarce. To facilitate decision-making we evaluated dynamic changes of alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and prostate specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikah, Phillip, Krabbe, Laura-Maria, Eminaga, Okyaz, Herrmann, Edwin, Papavassilis, Philipp, Hinkelammert, Reemt, Semjonow, Axel, Schrader, Andres-Jan, Boegemann, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790058/
https://www.ncbi.nlm.nih.gov/pubmed/26975660
http://dx.doi.org/10.1186/s12885-016-2260-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790058/
https://www.ncbi.nlm.nih.gov/pubmed/26975660
http://dx.doi.org/10.1186/s12885-016-2260-y

Ejemplares similares